ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2357

The Involvement of CCR3-CCL24 Axis in Endothelial to Mesenchymal Transition Process and Pulmonary Arterial Hypertension in Systemic Sclerosis Patients

Itzchak Amoyal1, Tzipi Hornik-Lurie2, Tali Zitman-Gal1, Hilit Levy3, Ilan Vaknin3, Liat Drucker4, Ishai Heusler5, Yair Levy1 and Shelly Tartakover Matalon1, 1Meir Medical Center, Autoimmune Research Laboratory, Kfar-Saba, Israel, 2Meir Medical Center, Data Research Department, Kfar-Saba, Israel, 3Chemomab Ltd, Tel Aviv, Israel, 4Meir Medical Center, Oncogenetics Laboratory, Kfar Saba, Israel, 5Meir Medical Center, Department of Obstetric and Genecology, Kfar-Saba, Israel

Meeting: ACR Convergence 2023

Keywords: Cell Trafficking Angiogenesis, chemokines, Fibroblasts, Other, Scleroderma, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2352–2369) Systemic Sclerosis & Related Disorders – Clinical Poster III: Translational Science

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by vascular injury and extensive tissue fibrosis of the skin and internal organs. Endothelial cells (ECs), a predominant target of the autoimmune attack, may undergo proliferation arrest, apoptosis, or differentiation to myofibroblasts, leading to complications including pulmonary arterial hypertension (PAH). The differentiation of ECs into myofibroblasts through endothelial mesenchymal transition (EndMT) represents a critical step in the blood vessels remodeling. ECs in the dermal microvascular tissue of patients with SSc exhibit robust expression of CCR3, the cognate receptor of CCL24,which has been found to be elevated in the serum and skin biopsies of SSc patients. The objective of this study is to evaluate the association between serum CCL24 levels and clinical characteristics of SSc patients, as well as the involvement of the CCL24-CCR3 axis in EndMT process.

Methods: CCL24 levels were evaluated in the sera of 75 SSc patients using ELISA. In this cohort, Pearson correlation tests were conducted to determine the relationship between CCL24 levels and performance measures such as the 6-minute walk test (6MW test). To study the potential association of CCL24 and CCR3 with the processes underlying EndMT, we established an in-vitro system in which the combination of TGFβ TNFα induced EndMT in human umbilical vein endothelial cells (HUVECs) and explored the expression of CCR3 and the effect of CCL24 supplementation and anti CCL24 antibody to this system. Studies included functional assessment of proliferation, cell death migration as well as evaluation of multiple markers of EndMT processes including αSMA, Vimentin, SNAIL, CD31 and VE-cadherin.

Results: The average level of CCL24 in the sera of patients with SSc with PAH (n=9) was significantly higher compared to the level of patients with SSc and without PAH (1136 vs 738 pg/ml, p< 0.05). Furthermore, a negative correlation was found between CCL24 levels and the 6MW test performance (r=-0.3, p< 0.05), reflecting reduced exercise capacity. The addition of TGFβ and TNFα resulted in EndMT in HUVECs, which was demonstrated by a significant increase in mesenchymal markers, reduced ECs markers, reduced cell number (52%, p< 0.05), and increased cell migration (112%, p< 0.05) relative to control. Furthermore, the EndMT process was associated with a significant increase in CCR3 levels (197%, p< 0.05). Notably, adding CCL24 in addition to TNFα and TGFβ further reduced cell count (from 52% to 33%, p< 0.05) and increased migration (from 112% to 127%, p=0.07). CCL24 neutralizing antibody (CM-101) completely inhibited cell migration and increased cell number.

Conclusion: This study provides evidence for the potential role of CCL24 in the pathogenesis of SSc and highlights its involvement in EndMT process resulting in disease complications such as PAH.


Disclosures: I. Amoyal: Chemomab Ltd, 5; T. Hornik-Lurie: Chemomab Ltd, 5; T. Zitman-Gal: Chemomab Ltd, 5; H. Levy: Chemomab Ltd, 3; I. Vaknin: Chemomab Ltd, 3; L. Drucker: Chemomab Ltd, 5; I. Heusler: Chemomab Ltd, 5; Y. Levy: Chemomab Ltd, 5; S. Tartakover Matalon: Chemomab Ltd, 5.

To cite this abstract in AMA style:

Amoyal I, Hornik-Lurie T, Zitman-Gal T, Levy H, Vaknin I, Drucker L, Heusler I, Levy Y, Tartakover Matalon S. The Involvement of CCR3-CCL24 Axis in Endothelial to Mesenchymal Transition Process and Pulmonary Arterial Hypertension in Systemic Sclerosis Patients [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/the-involvement-of-ccr3-ccl24-axis-in-endothelial-to-mesenchymal-transition-process-and-pulmonary-arterial-hypertension-in-systemic-sclerosis-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-involvement-of-ccr3-ccl24-axis-in-endothelial-to-mesenchymal-transition-process-and-pulmonary-arterial-hypertension-in-systemic-sclerosis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology